Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleNuclear Oncology

Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung

Rhona Stein, David M. Goldenberg, Suzanne R. Thorpe and M. Jules Mattes
Journal of Nuclear Medicine March 1997, 38 (3) 391-395;
Rhona Stein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Goldenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne R. Thorpe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Jules Mattes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 38, Issue 3
March 1, 1997
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung
Rhona Stein, David M. Goldenberg, Suzanne R. Thorpe, M. Jules Mattes
Journal of Nuclear Medicine Mar 1997, 38 (3) 391-395;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung
Rhona Stein, David M. Goldenberg, Suzanne R. Thorpe, M. Jules Mattes
Journal of Nuclear Medicine Mar 1997, 38 (3) 391-395;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers
  • Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
  • Improved Iodine Radiolabels for Monoclonal Antibody Therapy
  • Antibody Localization to B-Cell Lymphoma Xenografts in Immunodeficient Mice: Importance of Using Residualizing Radiolabels
  • Metabolite Production in Patients with Lymphoma After Radiometal-Labeled Antibody Administration
  • Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
  • Google Scholar

More in this TOC Section

  • Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates
  • Quantifying the Radiation Dosage to Individual Skeletal Lesions Treated with Samarium-153-EDTMP
  • Radiotoxicity After Strontium-89 Therapy for Bone Metastases Using the Micronucleus Assay
Show more Nuclear Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire